keyword
MENU ▼
Read by QxMD icon Read
search

Ledipasvir

keyword
https://www.readbyqxmd.com/read/28203449/a-cost-utility-analysis-of-different-antiviral-medicine-regimens-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection
#1
Seyed Moayed Alavian, Shekoufeh Nikfar, Abbas Kebriaeezadeh, Farhad Lotfi, Ehsan Sanati, Mohsen Rezaei Hemami, Khosro Keshavarz
BACKGROUND: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. OBJECTIVES: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014...
November 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28195877/direct-acting-antivirals-are-effective-for-chronic-hepatitis-c-treatment-in-elderly-patients-a-real-world-study-of-17%C3%A2-487-patients
#2
Feng Su, Lauren A Beste, Pamela K Green, Kristin Berry, George N Ioannou
BACKGROUND: The mean age of patients with chronic hepatitis C virus (HCV) infection in the USA has been increasing. Despite the increasing proportion of HCV-infected elderly patients, this group is under-represented in clinical trials of HCV treatment. AIM: We aimed to describe the real-world effectiveness of direct-acting antivirals (DAAs) among elderly patients. PATIENTS AND METHODS: We retrospectively identified 17 487 HCV-infected patients who were started on treatment with sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir-based regimens in the Veterans Affairs Healthcare System between 1 January 2014 and 30 June 2015...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28193102/identification-of-predictors-for-treatment-failure-in-hepatitis-c-virus-patients-treated-with-ledipasvir-and-sofosbuvir
#3
Jeffrey W Jansen, Gillian M Powderly, Travis W Linneman
BACKGROUND: New hepatitis C virus (HCV) therapies report cure rates of ~90% but are expensive. Identification of predictors for treatment failure could help decrease health care costs, limit unnecessary drug exposure and adverse events, and prevent drug-drug interactions. Failure to achieve rapid viral response (RVR), defined as detectable viral load at 4 weeks, has previously been identified as a predictor of treatment failure with some previous HCV therapies. OBJECTIVE: To evaluate RVR, and other potential variables, as predictors of treatment failure in patients treated with ledipasvir and sofosbuvir (LDV/SOF)...
February 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28184378/relapse-of-hcv-genotype-1b-infection-after-sofosbuvir-ledipasvir-treatment-presenting-as-de-novo-cryoglobulinemic-vasculitis
#4
Mohammad Qasim Khan, Alan D Moreno, Nora Joseph, George Kim, Claus J Fimmel
Relapse of hepatitis C virus (HCV) genotype 1 infection after combination therapy with sofosbuvir and ledipasvir is unusual. We report a treatment-naïve, non-cirrhotic patient in whom the relapse of genotype 1b HCV infection was accompanied by de novo cryoglobulinemic vasculitis and glomerulonephritis, requiring hemodialysis for acute renal failure. Sequence analysis revealed several resistance-associated variants in the HCV NS5a gene but not in NS3/4A. The patient's vasculitis was successfully treated with immunosuppression and plasmapheresis, followed by retreatment of HCV with a combination of sofosbuvir, simeprevir, and ribavirin...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/28184373/successful-treatment-of-mixed-hepatitis-c-genotypes-in-a-cirrhotic-patient-with-an-all-oral-interferon-free-regimen
#5
Ayman Ahmed Sakr, Jasmine M Hanifi, Ming Valerie Lin
Mixed hepatitis C virus (HCV) genotype infection is emerging with improved methods of detection. It is commonly seen in hemodialysis patients and intravenous drug users due to repeated HCV exposure and absence of protective immunity, and can contribute to treatment failure. Direct-acting antiviral regimens have been extensively studied in patients with different individual HCV genotypes; however, there are no reported data on their use in patients with mixed HCV genotype. We present a case of mixed HCV genotype 1a and 2 infection in a decompensated cirrhotic patient treated successfully with sofosbuvir, ledipasvir, and ribavirin...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/28183063/real-life-experience-with-direct-acting-antivirals-agents-against-hepatitis-c-infection-in-elderly-patients
#6
Iria Rodríguez-Osorio, Purificación Cid, Luis Morano, Ángeles Castro, Marta Suárez, Manuel Delgado, Luis Margusino, Héctor Meijide, Berta Pernas, Andrés Tabernilla, José D Pedreira, Álvaro Mena, Eva Poveda
BACKGROUND: New direct-acting antivirals agents (DAAs) are very safe and well tolerated. OBJECTIVES: The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. STUDY DESIGN: All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October 2015). RESULTS: A total of 120 HCV mono-infected patients were recorded...
March 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28174263/quantifying-antiviral-activity-optimizes-drug-combinations-against-hepatitis-c-virus-infection
#7
Yoshiki Koizumi, Hirofumi Ohashi, Syo Nakajima, Yasuhito Tanaka, Takaji Wakita, Alan S Perelson, Shingo Iwami, Koichi Watashi
With the introduction of direct-acting antivirals (DAAs), treatment against hepatitis C virus (HCV) has significantly improved. To manage and control this worldwide infectious disease better, the "best" multidrug treatment is demanded based on scientific evidence. However, there is no method available that systematically quantifies and compares the antiviral efficacy and drug-resistance profiles of drug combinations. Based on experimental anti-HCV profiles in a cell culture system, we quantified the instantaneous inhibitory potential (IIP), which is the logarithm of the reduction in viral replication events, for both single drugs and multiple-drug combinations...
February 7, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28171790/study-on-the-forced-degradation-behaviour-of-ledipasvir-identification-of-major-degradation-products-using-lc-qtof-ms-ms-and-nmr
#8
Debasish Swain, Gananadhamu Samanthula
Ledipasvir, a novel NS5A inhibitor is used in the management of hepatitis C virus infections. The drug was subjected to forced degradation studies as per the conditions prescribed in ICH Q1 (R2) guideline. Ledipasvir degraded in hydrolytic (acid, alkaline and neutral) and oxidative stress conditions. The drug was found to be stable in thermal and photolytic conditions. Eight novel degradation products were obtained and were well separated using an HPLC C18 stationary phase (150×4.6mm, 5μm) and mobile phase composed of formic acid/acetonitrile in gradient elution mode...
January 20, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28143559/health-utilities-using-sf-6d-scores-in-japanese-patients-with-chronic-hepatitis-c-treated-with-sofosbuvir-based-regimens-in-clinical-trials
#9
Zobair Younossi, Maria Stepanova, Masao Omata, Masashi Mizokami, Mercedes Walters, Sharon Hunt
BACKGROUND: Health utilities are preference-based measures for health states which are typically used in economic analyses to estimate quality-adjusted life years. Our aim is to report the standard SF-6D health utility scores in Japanese patients with hepatitis C virus (HCV) during treatment with different regimens. METHODS: Japanese patients were enrolled in clinical trials of sofosbuvir (SOF) used in combination with or without ledipasvir (LDV) and/or ribavirin (RBV)...
January 31, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28138756/treatment-with-sofosbuvir-and-ledipasvir-without-ribavirin-for-12%C3%A2-weeks-is-highly-effective-for-recurrent-hepatitis-c-virus-genotype-1b-infection-after-living-donor-liver-transplantation-a-japanese-multicenter-experience
#10
Yoshihide Ueda, Toru Ikegami, Nobuhisa Akamatsu, Akihiko Soyama, Masahiro Shinoda, Ryoichi Goto, Hideaki Okajima, Tomoharu Yoshizumi, Akinobu Taketomi, Yuko Kitagawa, Susumu Eguchi, Norihiro Kokudo, Shinji Uemoto, Yoshihiko Maehara
BACKGROUND: The optimal therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation has not yet been established. This study aimed to clarify the efficacy and safety of interferon-free therapy with sofosbuvir and ledipasvir without ribavirin for 12 weeks in Japanese patients with HCV genotype 1b infection after living donor liver transplantation. METHODS: A cohort study of living donor liver transplant recipients with recurrent HCV genotype 1b infection treated with sofosbuvir (400 mg/day) and ledipasvir (90 mg/day) was performed at six liver transplant centers in Japan...
January 30, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28137633/week-4-response-predicts-sustained-virologic-response-to-all-oral-direct-acting-antiviral-based-therapy-in-cirrhotic-patients-with-hepatitis-c-virus-genotype-3-infection
#11
Juan A Pineda, Luis E Morano-Amado, Rafael Granados, Juan Macías, Francisco Téllez, Miguel García-Deltoro, María J Ríos, Antonio Collado, Marcial Delgado-Fernández, Marta Suárez-Santamaría, Miriam Serrano, Celia Miralles-Álvarez, Karin Neukam
OBJECTIVE: The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against hepatitis C virus (HCV) genotype (GT) 3-infection with all-oral direct-acting antiviral (DAA)-based regimens. PATIENTS AND METHODS: From a prospective multicohort study, HCV GT3-infected patients who completed a course of currently recommended DAA-based therapy at 33 Spanish hospitals and who had reached SVR12 evaluation timepoint were selected...
January 27, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28137593/efficacy-of-ledipasvir-plus-sofosbuvir-for-8-or-12-weeks-in-patients-with-hepatitis-c-virus-genotype-2-infection
#12
Edward J Gane, Robert H Hyland, Yin Yang, Evguenia Svarovskaia, Luisa M Stamm, Diana M Brainard, John G McHutchison, Catherine A M Stedman
BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of response to treatment with sofosbuvir and ribavirin. However, ribavirin is associated with hemolytic events and is poorly tolerated by some patients. We evaluated the effectiveness of sofosbuvir and ledipasvir in treatment-naïve and treatment-experienced patients with HCV genotype 2, comparing 12 versus 8 weeks of treatment. METHODS: This Phase 2, open-label study included 2 cohorts in New Zealand...
January 27, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28134353/baseline-quasispecies-selection-and-novel-mutations-contribute-to-emerging-resistance-associated-substitutions-in-hepatitis-c-virus-after-direct-acting-antiviral-treatment
#13
Yugo Kai, Hayato Hikita, Naoki Morishita, Kazuhiro Murai, Tasuku Nakabori, Sadaharu Iio, Hideki Hagiwara, Yasuharu Imai, Shinji Tamura, Syusaku Tsutsui, Masafumi Naito, Meiko Nishiuchi, Yasuteru Kondo, Takanobu Kato, Hiroshi Suemizu, Ryoko Yamada, Tsugiko Oze, Takayuki Yakushijin, Naoki Hiramatsu, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara
Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) appear upon failure of treatment with direct-acting antivirals (DAAs). However, their origin has not been clarified in detail. Among 11 HCV genotype 1b patients who experienced virologic failure with asunaprevir (ASV)/daclatasvir (DCV), 10 had major NS5A L31M/V-Y93H variants after treatment. L31M/V-Y93H variants were detected as a minor clone before therapy in 6 patients and were the most closely related to the post-treatment variants by phylogenetic tree analysis in 4 patients...
January 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28130810/shift-in-disparities-in-hepatitis-c-treatment-from-interferon-to-daa-era-a-population-based-cohort-study
#14
N Z Janjua, N Islam, J Wong, E M Yoshida, A Ramji, H Samji, Z A Butt, M Chong, D Cook, M Alvarez, M Darvishian, M Tyndall, M Krajden
We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, or reported cases of hepatitis B and active tuberculosis in BC from 1990 to 2013 linked to medical visits, hospitalization, cancer, prescription drugs and mortality data. This analysis included all patients who filled at least one prescription for HCV treatment until 31 July 2015...
January 27, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28130599/progress-in-eradication-of-hcv-in-hiv-positive-patients-with-significant-liver-fibrosis-in-vienna
#15
Sebastian Steiner, Theresa Bucsics, Philipp Schwabl, Mattias Mandorfer, Bernhard Scheiner, Maximilian Christopher Aichelburg, Katharina Grabmeier-Pfistershammer, Peter Ferenci, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger
AIM: We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness. METHODS: In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed...
January 27, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28124511/ledipasvir-sofosbuvir-and-sofosbuvir-plus-ribavirin-in-patients-with-chronic-hepatitis-c-and-bleeding-disorders
#16
C E Walsh, K Workowski, N A Terrault, P E Sax, A Cohen, C L Bowlus, A Y Kim, R H Hyland, B Han, J Wang, L M Stamm, D M Brainard, J G McHutchison, A von Drygalski, F Rhame, M W Fried, P Kouides, G Balba, K R Reddy
INTRODUCTION: Chronic hepatitis C virus (HCV) infection is prevalent among patients with inherited bleeding disorders and is a leading cause of mortality in those with haemophilia. AIM: We evaluated the efficacy and safety of ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic HCV genotype 1-4 infection and an inherited bleeding disorder. METHODS: Ledipasvir-sofosbuvir was administered for 12 weeks to patients with genotype 1 or 4 infection and for 12 or 24 weeks to treatment-experienced cirrhotic patients with genotype 1 infection...
January 25, 2017: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/28118096/hepatitis-c-virus-and-interferon-free-antiviral-therapeutics-revolution-implications-for-pakistan
#17
Muhammad Sohail Afzal
Hepatitis C virus (HCV) is a major health concern worldwide as a leading cause of liver-related mortalities and morbidities. Pakistan ranks second among countries with endemic HCV infection; ∼11 million cases are reported so far. HCV burden is continuously rising in Pakistan, mainly because of unsafe blood transfusions, surgical procedures, dental procedures, untrained clinicians, reuse of syringes, barbers, and ear/nose piercing tools. Lack of awareness about HCV transmission routes among the general and high-risk population is a major hurdle in disease management...
January 24, 2017: Viral Immunology
https://www.readbyqxmd.com/read/28108232/ns5a-resistance-associated-substitutions-in-patients-with-genotype-1-hepatitis-c-virus-prevalence-and-effect-on-treatment-outcome
#18
Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, Alessandra Mangia, Kwang-Hyub Han, Ross Martin, Evguenia Svarovskaia, Hadas Dvory-Sobol, Brian Doehle, Charlotte Hedskog, Chohee Yun, Diana M Brainard, Steven Knox, John G McHutchison, Michael D Miller, Hongmei Mo, Wan-Long Chuang, Ira Jacobson, Gregory J Dore, Mark Sulkowski
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs). We analyzed data from 35 phase 1, 2, and 3 studies in 22 countries to determine the pretreatment prevalence of various NS5A RASs, and their effect on outcomes of treatment with ledipasvir-sofosbuvir in patients with genotype 1 HCV. METHODS: NS5A gene deep sequencing analysis was performed on samples from 5,397 patients in Gilead clinical trials...
January 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28106531/preclinical-characterization-of-the-novel-hcv-ns3-protease-inhibitor-gs-9256
#19
Huiling Yang, Chris Yang, Yujin Wang, Gerry Rhodes, Margaret Robinson, Guofeng Cheng, Xiaoping Qi, Hongmei Mo, Yang Tian, Rowchanak Pakdaman, X Christopher Sheng, Choung U Kim, William E Delaney
BACKGROUND: GS-9256 is an inhibitor of hepatitis C virus (HCV) NS3 protease with a macrocyclic structure and novel phosphinic acid pharmacophore. METHODS: Key preclinical properties of GS-9256 including in vitro antiviral activity, cross-resistance, and pharmacokinetic properties were investigated in non-human species. RESULTS: In genotype (GT) 1b Huh-luc cells with a replicon encoding luciferase, GS-9256 had a mean EC50 value of 20.0 nM, with minimal cytotoxicity...
January 20, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28079269/ledipasvir-plus-sofosbuvir-as-salvage-therapy-for-hcv-genotype-1-failures-to-prior-ns5a-inhibitors-regimens
#20
Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
There is little information on retreatment efficacy and predictors of the combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir) for patients who fail to respond to NS5A inhibitors. NS5A resistance variants are known to persist for long periods after such treatment. Here, we evaluated 54 patients with chronic HCV genotype 1b infection, free of decompensated cirrhosis and hepatocellular carcinoma, for sustained virological response after 12 weeks (SVR12) of once-daily treatment with 90 mg ledipasvir and 400 mg sofosbuvir...
January 12, 2017: Journal of Medical Virology
keyword
keyword
40094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"